Ivosidenib in Treating Patients With Advanced Solid Tumors ...

Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in ...

Ivosidenib demonstrates “impressive single-agent efficacy, with durable responses in these high-risk patients with relapsed or refractory AML,” said Dr DiNardo.

Updated survival outcomes with ivosidenib in patients with ...

The results of the phase III ClarIDHy trial led to the FDA approval of ivosidenib as a therapeutic option for patients with locally advanced ...

Ivosidenib Provides Prolonged Progression-Free Survival

Patients with advanced cholangiocarcinoma and an isocitrate dehydrogenase 1 (IDH1) mutation showed clinical benefit and improved progression- ...

Ivosidenib in IDH1-mutant, chemotherapy-refractory ... - The Lancet

... patients with advanced solid tumors. Invest New Drugs. 2020; 38:433 ... Combination versus mono-therapy as salvage treatment for advanced biliary ...

Ivosidenib Maintains Quality of Life in Patients With ...

Ivosidenib (Tibsovo) was linked to a promising preservation of health-related quality of life (HRQOL) among patients with advanced chemotherapy-refractory ...

Ivosidenib in IDH1-mutant, chemotherapy-refractory ...

Ivosidenib (AG-120) is an oral, potent, targeted inhibitor of mutated IDH1 approved for patients with newly diagnosed acute myeloid leukaemia who are ineligible ...

Health Technology Briefing July 2022 - NIHR Innovation Observatory

... treatment of previously treated advanced ... Final Overall Survival. Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma ...

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or ...

Overall, 93 patients with mIDH1/2 advanced solid tumors were treated, including 52 patients with glioma (Table 1). Table 1. Baseline characteristics ...

Ivosidenib in Treating Patients With Advanced Solid Tumors ...

Ivosidenib in treating patients with advanced solid tumors, lymphoma, or histiocytic disorders with IDH1 mutations (a pediatric match treatment trial)

Results of A Phase 1 Study on Ivosidenib for Patients with Advanced ...

In patients with chondrosarcoma, ivosidenib showed minimal toxicity, substantial 2-HG reduction, and durable disease control. Future studies of ivosidenib ...

Phase I Assessment of Safety and Therapeutic Activity of ...

In this multipart dose escalation and dose expansion study, BAY1436032 was administered to subjects with advanced mIDH1 solid tumors. BAY1436032 ...

Overall Survival Favorable With Ivosidenib for Advanced ...

A final overall survival analysis found improved results and a tolerable safety profile for patients with advanced IDH1-mutated ...

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

Patients were followed for a median of 12.4 months. Event-free survival was significantly longer in the ivosidenib-and-azacitidine group than in ...

Ivosidenib in Patients With Advanced IDH1-Mutated Chondrosarcoma

Tap, MD, and colleagues found that the selective mutant-IDH1 inhibitor ivosidenib produced no objective responses but resulted in durable ...

Phase I study of the mutant IDH1 inhibitor ivosidenib

We report outcomes of patients with advanced chondrosarcoma in an ongoing study exploring ivosidenib treatment. PATIENTS AND METHODS This phase I multicenter ...

Ivosidenib Earns Priority Review for IDH1-Mutated ... - Cancer Network

The FDA has accepted and granted priority review to a supplemental new drug application for ivosidenib (Tibsovo) to treat patients with ...

Safety and activity of ivosidenib in patients with IDH1-mutant ...

... Ivosidenib, a potent small-molecule inhibitor of mIDH1 tumors, was first approved for treating patients with advanced acute myeloid leukemia [56]. After a ...

211192Orig1s000 - accessdata.fda.gov

Table 58: Duration of Exposure1 to Ivosidenib in Solid Tumor Patients and Healthy Volunteers ... advanced solid tumors (PK, Safety,. ORR).

Ivosidenib induces deep durable remissions in patients with newly ...

Ivosidenib is a specific inhibitor of the mutant IDH1 enzyme that drives a subset of acute myeloid leukemias. This Plenary Paper is the ...

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an ...

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors · Bin Fan, I.